CD274 and non-small cell lung carcinoma: It has been shown that atezolizumab treatment improves survival in NSCLC independent of PD-L1 expression status (11, 12), and the results of several other studies have shown that cases with PD-L1-negative tumours still obtain a significant benefit from ICI treatment (3, 4, 10).